{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:23:38Z","timestamp":1792113818331,"version":"4.4.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017467","name":"Amplyx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,5,17]]},"abstract":"<jats:p>\n                    Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and\/or invasive candidiasis caused by\n                    <jats:named-content content-type=\"genus-species\">Candida auris<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/aac.01419-22","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T10:00:24Z","timestamp":1680775224000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":93,"title":["Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris\n                    <i>:<\/i>\n                    Results from a Phase 2 Trial"],"prefix":"10.1128","volume":"67","author":[{"given":"Jose A.","family":"Vazquez","sequence":"first","affiliation":[{"name":"Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Boffard","sequence":"additional","affiliation":[{"name":"Milpark Hospital, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima","family":"Paruk","sequence":"additional","affiliation":[{"name":"Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bien","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6815-2647","authenticated-orcid":true,"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ople","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Wedel","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Oborska","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hodges","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2302.161486"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03364-19"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.131765"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2008.00083.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01588-17"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14121"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2125349"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa193"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-2027-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0132-5"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00238-18"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb300235m"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02319-17"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00523-18"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02542-17"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky302"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00517-21"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-20"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-20"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01120-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1209"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040239"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.457"},{"key":"e_1_3_2_28_2","unstructured":"U.S. National Library of Medicine. 2017. Open-label study to evaluate the efficacy and safety of oral ibrexafungerp (SCY-078) in patients with candidiasis caused by Candida auris (CARES) (CARES). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03363841. Accessed 25 January 2023."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof5030067"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof8030267"},{"key":"e_1_3_2_31_2","unstructured":"U.S. Department of Health and Human Services. 2019. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed 14 March 2022."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7029a2"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.09.007"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01146-21"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myab079"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.4102\/sajid.v34i1.163"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1370"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01419-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01419-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T09:08:35Z","timestamp":1684314515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01419-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,17]]}},"alternative-id":["10.1128\/aac.01419-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01419-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01419-22"}}